Phase I/II study of KB-103 meets all primary efficacy and safety endpoints at interim data analysis Oct. 16, 2018
Foamix reports further data from third phase III trial of FMX-101 for moderate to severe acne Oct. 2, 2018
P. acnes CAMP factor-associated inflammation in acne vulgaris: a potential vaccination strategy Sep. 28, 2018
Concert Pharmaceuticals amends protocol of phase IIa trial with CTP-543 in alopecia areata Sep. 27, 2018
RSS